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ABSTRACT 
Members of the bacterial genus Streptomyces are well known for their ability to produce an 
exceptionally wide selection of diverse secondary metabolites. These include natural 
bioactive chemical compounds which have potential applications in medicine, agriculture 
and other fields of commerce. The outstanding biosynthetic capacity derives from the 
characteristic genetic flexibility of Streptomyces secondary metabolism pathways: i) 
Clustering of the biosynthetic genes in chromosome regions redundant for vital primary 
functions, and ii) the presence of numerous genetic elements within these regions which 
facilitate DNA rearrangement and transfer between non-progeny species. Decades of 
intensive genetic research on the organization and function of the biosynthetic routes has 
led to a variety of molecular biology applications, which can be used to expand the 
diversity of compounds synthesized. These include techniques which, for example, allow 
modification and artificial construction of novel pathways, and enable gene-level detection 
of silent secondary metabolite clusters. Over the years the research has expanded to cover 
molecular-level analysis of the enzymes responsible for the individual catalytic reactions. 
In vitro studies of the enzymes provide a detailed insight into their catalytic functions, 
mechanisms, substrate specificities, interactions and stereochemical determinants. These 
are factors that are essential for the thorough understanding and rational design of novel 
biosynthetic routes.  
The current study is a part of a more extensive research project (Antibiotic Biosynthetic 
Enzymes; www.sci.utu.fi/projects/biokemia/abe), which focuses on the post-PKS tailoring 
enzymes involved in various type II aromatic polyketide biosynthetic pathways in 
Streptomyces bacteria. The initiative here was to investigate specific catalytic steps in 
anthracycline and angucycline biosynthesis through in vitro biochemical enzyme 
characterization and structural enzymology. The objectives were to elucidate detailed 
mechanisms and enzyme-level interactions which cannot be resolved by in vivo genetic 
studies alone. The first part of the experimental work concerns the homologous polyketide 
cyclases SnoaL and AknH. These catalyze the closure of the last carbon ring of the tetracyclic 
carbon frame common to all anthracycline-type compounds. The second part of the study 
primarily deals with tailoring enzymes PgaE (and its homolog CabE) and PgaM, which are 
responsible for a cascade of sequential modification reactions in angucycline biosynthesis.  
The results complemented earlier in vivo findings and confirmed the enzyme functions in 
vitro. Importantly, we were able to identify the amino acid -level determinants that influence 
AknH and SnoaL stereoselectivity and to determine the complex biosynthetic steps of the 
angucycline oxygenation cascade of PgaE and PgaM. In addition, the findings revealed 
interesting cases of enzyme-level adaptation, as some of the catalytic mechanisms did not 
coincide with those described for characterised homologs or enzymes of known function. 
Specifically, SnoaL and AknH were shown to employ a novel acid-base mechanism for aldol 
condenzation, whereas the hydroxylation reaction catalysed by PgaM involved unexpected 
oxygen chemistry. Owing to a gene-level fusion of two ancestral reading frames, PgaM was 
also shown to adopt an unusual quaternary sturucture, a non-covalent fusion complex of two 
alternative forms of the protein. Furthermore, the work highlighted some common themes 
encountered in polyketide biosynthetic pathways such as enzyme substrate specificity and 
intermediate reactivity. These are discussed in the final chapters of the work. 
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1.1 Streptomyces diversity and secondary metabolism 
1.1.1 Background to antibiotic research  
The beginning of the antibiotic research era was marked by the discovery of penicillin, 
a secondary metabolite of Penicillium notatum mold, by Alexander Fleming in 1928. 
Although it was not until over 10 years later the first successful human antibiotic 
treatments were carried out, realization of the potential of microbes to produce useful 
bioactive compounds and advances in mass-producing these products soon launched 
world-wide interest in natural product research. Massive international soil screening 
projects were carried out in Europe, North America and Japan through 1950’s to 70’s 
aiming to find producers of new effective drug molecules. One of the most prominent 
groups of microbial secondary metabolite producers proved to be common gram-
positive soil bacteria of the genus Streptomyces. These bacteria are abundant 
inhabitants in soil, and display exceptional metabolic diversity. Despite their leading 
role over the “golden years” of antibiotic research, however, only a limited number of 
the thousands of isolated bioactive compounds proved pharmacologically effective and 
not too toxic for human use. Since then the focus has polarized towards other 
producers such as fungi, lichens and so-called rare actinomycete species. Yet even 
today Streptomyces-derived metabolites continue to uphold a central role in the clinical 
treatment of bacterial infections and various types of cancer. For decades Streptomyces 
have also been subjected to intense genetic study of the secondary metabolism 
pathways. Gradually the research has expanded towards protein-level study to reveal 
molecular mechanisms behind the biosynthetic diversity - to understand the limitations 
and possibilities of different technologies in the design of novel compounds with 
improved clinical effects and toxicity profiles. 
1.1.2 Diversity of Streptomyces species 
One gram of soil may contain over 1.5 x 1010 microbial cells (Torsvik et al., 1990) 
emphasizing the concepts of competition and competitive advantage in this natural 
habitat. Based on mathematical models and genetic diversity, the number of different 
strains within such populations has been estimated to range from nearly 40 000 (Curtis 
et al., 2002) to up to several millions species (Gans et al., 2005) in pristine 
uncontaminated soil. Many of the most important non-fungal contributors to this 
diversity are members of a heterogeneous group of gram-positive bacteria 
actinomycetes (order Actinomycetales), which have a vital role in carbon turnover in 
nature as decomposers of organic matter such as cellulose, lignin and chitin. The 
largest and perhaps the most significant taxonomic sub-group of this order is the genus 
Streptomyces (family Streptomycetaceae), which is known and extensively studied for 
having a complex life cycle and an exceptional capacity to produce bioactive 
metabolites of potential medical, clinical and agricultural interest. Historically, 
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taxonomic classification of Streptomyces has been difficult due to extensive 
morphological, physiological and biochemical heterogeneity. Even with today’s 
chemotaxonomic and molecular techniques combined with numerical taxonomic 
methods, distinction of taxa within the genus is not clear-cut, and the results vary 
depending on the approach and identification matrices used (Anderson & Wellington, 
2001; Manfio et al., 1995). In 1999 the number of validly assigned Streptomyces 
species has been stated to be over 450 (al-Tai et al., 1999). The corresponding number 
is presently 542 and 38 subspecies as cited in the Approved Lists of Bacterial Names 
(Skerman et al., 1980) or validly published in the International Journal of Systematic 
Bacteriology (IJSB) or in the International Journal of Systematic and Evolutionary 
Microbiology (IJSEM). Underlining the lack of systematic tools for specification and 
comparison, the number of taxa listed under the genus on the NCBI (National Center 
for Biotechnology Information; www.ncbi.nlm.nih.gov) taxonomy server is presently 
in several thousands. 
1.1.3 Streptomyces life cycle and adaptation  
Streptomyces are exceptionally well adapted to the competition and the quickly 
changing conditions of the soil. This is reflected in the complexity of their life cycle by 
bacterial standards. During the vegetative phase of their growth when nutrients are 
abundant the cells elongate and invade the soil by forming a network of branched 
filaments called mycelium. Environmental stress such as lack of nutrients triggers the 
formation of aerial hyphae (sporophores) which extend above the colony or into the air 
pockets in soil and eventually septate into separate spores (conidia). The molecular 
mechanisms regulating the morphological and chemical differentiation are still poorly 
understood. At the onset of periods of metabolic stress Streptomyces species synthesize 
and accumulate triacylglycerols as high-energy reserve compounds (Arabolaza et al., 
2008; Olukoshi & Packter, 1994), a capability very uncommon to prokaryotes outside 
the Actinomycetales order  (Alvarez & Steinbuchel, 2002). Non-optimal growth 
conditions also set off a transition to secondary metabolism functions, including the 
induction of the production of various bioactive compounds which are excreted as a 
chemical defense against microbial rivals. These include a wealth of growth inhibitors 
and microbicidal compounds. In addition, metabolites which participate in active 
transport of scarce nutrients to provide competitional advantage are also synthesized. 
The number and functional range of the distinct compounds naturally produced by 
Streptomyces bacteria reflects their genetic potential and flexibility, and their 
substantial interest to humans. 
1.1.4 Streptomyces as a source of bioactive metabolites  
It has been estimated that of the excess one million reported natural products, over 
50000 are of microbial origin (Berdy, 2005). About half of these have been associated 
with a certain cellular or molecular-level biological function and, consequently, are 
commonly referred to as “bioactive compounds”. These include over 17000 so-called 
“classical antibiotics” with antimicrobial, anti-tumor and/or antiviral activities, as well 
as compounds such as growth promoters, immunosuppressants, herbicides and anti-
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paracitic agents. Remarkably, about a third of all microbial bioactive compounds 
reported by the year 2002 (~7600 out of ~22000 metabolites) derive from Streptomyces 
species (Berdy, 2005). According to mathematical predictions, this is yet a minor 
fraction of the total number of different compounds potentially produced by the genus 
(Watve et al., 2001).  
Unequivocal classification of the metabolites found in Streptomyces is complicated by 
the vast structural and functional diversity, but most fall under one of the three major 
compound classes; peptide-type compounds, macrocyclic lactones and various quinone 
derivatives. If the metabolites are grouped based on their biosynthetic origin, one of the 
most significant entities are the polyketide compounds, which comprise a major share 
of natural products used in human medicine. These include compounds such as 
tetracycline (Chopra & Roberts, 2001; Zakeri & Wright, 2008) and erythromycin 
(McGuire et al., 1952; Shah, 1998) effective against bacterial infections, the antifungal 
agents candicidin (Waksman et al., 1965) and amphotericin (Abadi, 1995; Dutcher, 
1968), anthracycline derivatives such as doxorubicin (Skovsgaard & Nissen, 1975) 
used in cancer treatment, and the immunosuppressant rapamycin (Saunders et al., 
2001; Sehgal, 2003; Vezina et al., 1975) used to prevent organ transplant rejection. 
Polyketides can be subdivided into categories (type I, II and III) on the basis of their 
biosynthesis (see section 1.3 for a description of type II polyketide biosynthesis). Type 
II aromatic polyketides are further classified into 7 structurally distinct groups, 
anthracyclines, angucyclines, aureolic acids, tetracycline-type compounds, 
tetracenomycins, pradimicins and benzoisochromanequinones (BIQ) (Figure 1). 
Anthracyclines and angucyclines, the subjects of this study, are described in more 




Figure 1. Typical examples of different groups of type II aromatic polyketide compounds: Doxorubicin 
(anthracycline), jadomycin B (angucycline), tetracycline, actinorhodin (benzoisochromanequinone), 
mithramycin A (aureolic acid), pradimicin A and tetracenomycin C.  
1.1.5 Need for new natural products and use by humans 
Despite the vast selection of reported compounds, there is an ever-increasing need for 
new pharmacologically active molecules and potential drug leads. One of the standing 
goals is to find alternatives to overcome adverse clinical effects which presently 
compromise the use of many drugs in human therapeutics. This is classically 
exemplified by anthracycline-induced cumulative cardiotoxicity (Chen et al., 2007; 
Gianni et al., 2008; Keefe, 2001) which together with rapidly emerging multidrug 
resistance (MDR) (Nobili et al., 2006) typically restrains prolonged cancer treatment. 
As demonstrated by the immunosuppressor cyclosporin A (CSA) used for reversal of 
MDR (Aouali et al., 2005) and antioxidants applied to overcome anthracycline 
cardiotoxicity (Hideg & Kalai, 2007), the screening of new compound derivatives is 
closely accompanied by the study of auxiliary effectors for improved clinical results. 
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Another obvious motive for the research is to provide alternative treatment against 
infectious diseases caused by resistant pathogenic micro-organisms, bacteria, viruses, 
parasites or fungi, which continue as the leading cause of death and a drain of 
resources world-wide (World Health Report 2007 / WHO; www.who.int/whr/en). 
Whatever the specific use may be, better understanding of the molecular mechanics 
behind various clinical conditions has in part rationalized the field of drug design, 
while the development of high throughput screens for different molecular targets 
requires a constant input of new ligands.   
Only a small fraction of the bioactive compounds found in nature have been applied in 
any commercial purposes in medicine, pharmacology or agriculture. However, as 
illustrated by the comprehensive review by Newman and Cragg (Newman & Cragg, 
2007), natural products continue to uphold a central role in the development of new 
drugs. Of the 1184 new chemical entities (NCEs) approved worldwide for human use 
between the years 1981 and 2006 over 50% were natural products or their derivatives 
(Newman & Cragg, 2007). The corresponding proportion of naturally-derived and/or 
semisynthetically modified antibacterial drugs was over 70% and for anticancer drugs 
just under 50%. This highlights the continuing role of multidisciplinary research in the 
discovery of new compounds from natural sources, including the yet largely 
unexplored genetic biosynthetic potential of Streptomyces. 
1.2 Organization of the Streptomyces genome: Evolved to evolve 
and diverge  
1.2.1 Streptomyces genome background  
The research related to Streptomyces genetics date back to mid 60’s when the first 
genetic recombination linkage map studies of S. coelicolor A3(2) were carried out by 
David Hopwood (Hopwood, 1965). Since then, inspired by the evident genetic potential 
in the synthesis of bioactive molecules, profound gene-level studies have continued. 
These have been reviewed by various authors (Chen et al., 2002; Hopwood, 1999; 
Hopwood, 2006; Metsä-Ketelä et al., 2007). So far the genomes of four Streptomyces 
species have been fully sequenced: S. coelicolor 8 667 507 bp/7825 ORFs (Bentley et 
al., 2002) S. avermitilis 9 025 608 bp/7574 ORFs (Ikeda et al., 2003), S. griseus 8 545 
929bp/7138 ORFs (Ohnishi et al., 2008) and S. scabies 10 148 695 bp (Sanger Institute 
Project, unpublished 11/2008; www.sanger.ac.uk/Projects/S_scabies). Streptomyces 
genome is unusually large with a high GC content (~70%), and organized in a linear 
chromosome with primary and secondary gene functions clearly distributed at distinct 
conserved and more variable regions. The chromosome replicates bidirectionally from 
a centered origin of replication in a process involving terminal protein (TP) mediated 
circularization. The secondary metabolic functions are mainly located at the distal ends 
of the chromosome arms. Importantly, this chromosomal arrangement is closely 
affiliated with the evolution and divergence of the secondary metabolite routes found 
in Streptomyces (Fischer et al., 1997b). As will be seen, this is also reflected at the 
level of individual enzymes catalyzing the biosynthetic reactions along these pathways. 
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1.2.2 Genome size reflects a diversity of functions  
The first obvious characteristic of Streptomyces genome is its exceptional size. Despite 
rather extensive variation between the genome size of different species, ranging from 
about 6.5Mb in S. ambofaciens (Leblond et al., 1990) to over 10Mb reported for S. 
scabies, they are amongst the largest encountered in bacteria. Typically Streptomyces 
harbor more open reading frames than the single celled eukaryote S. cerevisiae 
(Goffeau et al., 1996), and in comparison to the sporulating gram-positive soil 
bacterium Bacillus subtilis, the genome size and the number of potential open reading 
frames are roughly double  (Kunst et al., 1997). The enormous genome size reflects the 
complex life cycle of Streptomyces bacteria and adaptability to different stress factors 
encountered in the quickly changing conditions of the soil. A large fraction of the total 
genes have been suggested to be involved with environmental adaptation, response to 
external stimuli, and regulation between the primary and secondary metabolism 
functions. The focal point of genetic research has centered on these “excess” gene 
functions, primarily the production of bioactive secondary metabolites, genes 
responsible for the biosynthetic events and their regulation. 
1.2.3 Linear genome and distribution of functions  
Distinctively, although not exclusively in the bacterial kingdom, the Streptomyces 
chromosome is linear (Lin et al., 1993; Volff & Altenbuchner, 2000). Different gene 
elements are distributed unevenly between the center and the distal regions of the 
chromosome, and are expressed during different phases of the life cycle 
(Karoonuthaisiri et al., 2005). The central core region of roughly 6.5 Mb harbors a 
majority of essential primary metabolism genes such as those responsible for cell 
division, DNA replication, transcription and translation. Between different 
Streptomyces species, this region appears highly conserved in genetic content as well 
as gene order (Ikeda et al., 2003). In contrast, the telomeric chromosomal arm regions 
show substantial variability and polymorphism from one species to another and contain 
non-essential genes largely redundant for primary metabolism (Bentley et al., 2002; 
Ikeda et al., 2003). These regions carry secondary metabolism gene elements related to 
adaptation to physical stress conditions, and most biosynthetic clusters involved in 
polyketide antibiotic production.  
1.2.4 Genome susceptible to alteration  
The high frequency of genetic alteration in the Streptomyces chromosomal arm regions 
was characterized as “instability” or “plasticity” years before molecular mechanisms 
behind the phenomenon were known. The variability is not related to linearity as such 
(Fischer et al., 1997a; Wenner et al., 2003), but to specific gene elements in the 
chromosomal arm regions, which facilitate various processes of extensive DNA 
rearrangement, deletion and duplication. These regions contain long terminal inverted 
repeat (TIR) sequences which vary in size up to hundreds of kilobases, and participate 
in homologous recombination events resulting in intra-chromosomal arm replacement 
and rearrangement (Fischer et al., 1998; Widenbrant et al., 2007). This is expectedly 
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enhanced by the geometry of the chromosome, as a single crossing-over event is 
sufficient for the exchange process in a linear DNA (Volff & Altenbuchner, 1998). 
TIRs are also found in linear plasmids which can integrate into the host genome 
(Gravius et al., 1994; Kinashi et al., 1992; Pandza et al., 1998) facilitating plasmid-
mediated interspecies conjugation  (Kinashi et al., 1992; Wang et al., 1999). In 
addition, an exceptionally large number of transposase genes,  phage-plasmid integrase 
genes, and corresponding transposable element sequences have been concentrated in 
the chromosomal arm regions (Bentley et al., 2002; Ikeda et al., 2003). Altogether, 
these sequences actively participate in the rearrangement of the genetic material within 
and between Streptomyces species, providing a genetic basis for the diversity of 
bioactive compounds observed in nature. 
Phylogenetic sequence analysis has provided evidence that genes involved in 
Streptomyces secondary metabolism are subjected to horizontal gene transfer (HGT) 
(Egan et al., 2001; Metsä-Ketelä et al., 2002), a central phenomenon in molecular 
evolution between non-progeny bacterial species (Jain et al., 2002; Jain et al., 2003). In 
the work of Metsä-Ketelä and co-workers, extensive sequence comparison of over 100 
Streptomyces species revealed disparate clustering of specific gene elements central to 
aromatic polyketide biosynthesis and the corresponding 16S rRNA sequences, 
demonstrating that exchange of genetic material from one species to another must have 
contributed to the natural diversification of the biosynthetic pathways. Recently, direct 
inter-species HGT has also been reported between the more distantly related taxa 
Streptomyces padanus and Rhodococcus fascians (Kurosawa et al., 2008). This study 
illustrated that transfer of Streptomyces DNA in a competitive co-culture was 
accompanied by the appearance of capacity to produce novel aminoglycoside 
antibiotics by the recipient.  
1.2.5 Secondary metabolism biosynthetic clusters 
As opposed to primary metabolism genes which are spread out in the genome, the 
genes involved in secondary metabolism pathways are characteristically arranged 
together in defined continuous genetic regions or “clusters”. Importantly, this 
organization allows the detection and isolation of complete functional biosynthetic 
pathways for biochemical study and manipulation. The clusters typically compose of 
up to dozens of genes  required for the synthesis of a specific metabolite including 
carbon chain assembly, modification and regulation (see Figure 2).  
The true distribution and divergence of secondary metabolite clusters in nature cannot 
be estimated on the basis of culture screens, as only a small minority of potential 
producers are culturable in laboratory conditions and only a fraction of these can be 
induced to produce the target metabolites. However, the genetic sequence data 
available at present has enabled different genome-mining approaches to detect and 
characterize biosynthetic pathways expected to produce formerly unknown products 
(Challis, 2008a; Corre & Challis, 2007; Gross et al., 2007). Based on genome 
sequencing projects, S. coelicolor harbors 20 distinct secondary metabolite clusters 
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(Bentley et al., 2002), whereas 30 putative clusters are found in S. avermitilis (Ikeda et 
al., 2003). These include biosynthetic pathways for different siderophores, hopanoids, 
terpenes and pigments (Bentley et al., 2002; Ikeda et al., 2003; Omura et al., 2001)as 
well as for various antibiotic compounds. S. coelicolor produces three known 
antibiotics; the type II polyketide actinorhodin, oligopyrrole prodiginine antibiotic 
complex and a non-ribosomal peptide antibiotic CDA (Bentley et al., 2002). S. 
avermitilis has biosynthetic clusters for a number of type I polyketide compounds 
including avermectin, two putative type II aromatic polyketides and non-ribosomal 
peptide antibiotics. The most recently published genome sequence of S. griseus 
(Ohnishi et al., 2008) reveals 34 secondary metabolite clusters, including clusters for 
the aminoglycoside antibiotic streptomycin, two putative lantibiotic peptide antibiotics 
and several non-ribosomal peptide antibiotics. Although complete genomic sequence 
data is not available aside from these examples, numerous individual antibiotic clusters 
from other Steptomyces species have been detected and characterized to varying 
degrees.  
The NCBI CoreNucleotide database provides a means to approximate the variety of 
presently identified and sequenced clusters related to Streptomyces secondary 
metabolism. Search for “Streptomyces cluster” expected to cover most of the deposited 
target sequences, yields presently over 1200 distinct hits, most of which are 
overlapping partial biosynthetic clusters or refer to bacterial taxa other than 
Streptomyces. Inspection and manual processing of the search results one by one 
reveals about two hundred partial or complete clusters assigned to identified 
Streptomyces bioactive metabolite (or metabolite group) biosynthesis. These originate 
from altogether about a hundred different Streptomyces taxa, species, subspecies or 
strains. Many species were found to contain several different clusters, as in the case of 
Streptomyces antibioticus which harbours identified pathways for oleandomycin, 
oviedomycin and simocyclinone biosynthesis. In parallel, several pathways have been 
discovered in different species, such as the validamycin cluster in S. hygroscopicus and 
S. tsusimaensis, or the landomycin E cluster in S. cyanogenus and S. globisporus. 
Using a more strictly limited search “Streptomyces cluster complete” for parallel 
comparison and validation, about 60 of the gene clusters were denoted as complete 
sequences, covering all the known groups of bioactive metabolites produced by 
different Streptomyces species. The only complete cluster sequenced from two sources 
was the aminocyclitol antibiotic spectinomycin route cloned from S. spectabilis and S. 
flavopersicus. Apparently, the results are not comprehensive and only provide a 
generalized estimation. Many fully sequenced clusters, including those encoding for 
CDA and avermectin, are left out because, presumably, they have not been deposited in 
the data bank as separate complete entities. 
So far the biosynthetic gene clusters of eight different anthracycline-type aromatic 
polyketide compounds have been cloned and sequenced entirely or in part (Metsä-
Ketelä et al., 2007). As related to this work (I-III), these include the nogalamycin 
cluster sno from S. nogalater strain ATCC 21451 (Ylihonko et al., 1996) and the 
partially sequenced aclacinomycin biosynhetic clusters from two S. galilaeus strains 
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ATCC31615 (Räty et al., 2000; Räty et al., 2002b) and 3AR-33 (Chung et al., 2002) 
(Figure 2). The available genetic sequence data on related angucycline-type 
compounds is more limited (Decker & Haag, 1995; Han et al., 1994; Palmu et al., 
2007; Westrich et al., 1999), largely because most of the existing biosynthetic 
pathways are silent in laboratory conditions (Metsä-Ketelä et al., 2002) and undetected 
in conventional production screens. The two partially sequenced angucycline clusters 
subjected to this study (IV-VI), pga from Streptomyces sp. PGA64 and cab from 
Streptomyces sp. H021, are examples of pathways detected by DNA fingerprinting 
from non-producing phenotypes (Palmu et al., 2007) (Figure 2). 
 
Figure 2. Graphic representation of the genes in sequenced biosynthetic clusters pga, cab, akn and sno. 
The genes encoding for the target enzymes of this study are shown as labelled arrows. 
1.3 Biosynthesis of type II aromatic polyketides and genetic 
engineering 
Type II aromatic polyketide biosynthetic routes have been extensively studied to 
elucidate the nature and order of the sequential enzymatic reactions. One typical gene-
level approach employs extrachromosomal expression plasmids harboring complete or 
partial biosynthetic clusters, which can be induced in heterologous host cells to 
produce polyketide intermediates for analysis (Challis, 2008b). Together with enzyme-
level in vitro functional and structural studies the details of many biosynthetic steps are 
now known and have been reviewed by various authors (Hertweck et al., 2007; Metsä-
Ketelä et al., 2007; Niemi et al., 2002). 
Type II aromatic polyketides are synthesised in a cascade of sequential enzyme 
catalysed reactions analogous to fatty acid biosynthesis. First, a linear polyketide chain 
of typically 16-26 carbons (Ridley et al., 2008) is assembled from a starter unit (acetate 
or less commonly propionate or longer) and two carbon acetate extender units in 
repeated Claisen condensation reactions. This is carried out by the so-called minimal 
polyketide synthase enzyme complex (minPKS) which consists of ketoacylsynthase/ 
chain length factor heterodimer (KSa/KSß or KS/CLF) and acyl carrier protein (ACP). 
The highly reactive carbon chain is then reduced, cyclized and aromatized to produce 
the first carbon ring. Aside from the carbon chain length, the biosynthesis of most type 
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II aromatic polyketides follows the same route up to this point (Figure 3). 
Anthracycline-type compounds are then typically converted into a common tetracyclic 
precursor aklavinone (AKV) (Arora, 1985). The reaction sequence involves the 
formation of the next two carbon rings, oxygenation (7,12 -quinone formation) and 
C10 substituent methylation, which in the aclacinomycin pathway yields aklanonic 
acid methyl ester (AAME). This is followed by the cyclization of the fourth ring, and 
ketoreduction at C7. The nogalamycin pathway is one of the rare exceptions to this 
route, and proceeds via nogalonic acid methyl ester (NAME) to nogalavinone, a 
product with the opposite stereochemistry at C9. In the biosynthesis of angucycline-
type compounds the corresponding steps are catalyzed by a specific cyclase, which 
alone completes the tetracyclic carbon ring backbone and produces UWM6, a common 
intermediate in various angucycline pathways. In the following stages different 
pathways diverge into distinct routes by the action of post-PKS tailoring enzymes 
responsible for specific glycosylation, oxygenation, ketoreduction, and dehydration 
reactions, steps which account for the vast diversity of the secondary metabolites 
encountered in nature. In the context of the present work the term "tailoring" 
(reaction/enzyme) is used loosely and expected also to cover the 4th ring cyclization 
step of anthracyclines. 
Scientific interest in the biosynthetic routes derives largely from their inherent 
flexibility, which allows recombination of genes or partial clusters from different 
origins to generate entirely new pathways. Ever since the development of specific 
molecular biology techniques, combinatorial biosynthesis and pathway engineering 
approaches have been explored for their potential in designing novel metabolites  
(Hutchinson & McDaniel, 2001; Kantola et al., 2003; McDaniel et al., 1995; McDaniel 
et al., 1999; Weber et al., 2003). The first reported demonstration of possibilities of 
genetic engineering was the production of mederrhodin, a hybrid between medermycin 
and actinorhodin by David Hopwood and coworkers (Hopwood et al., 1985). Since 
then the methods have been applied, for example, to combine genes from different 
pathways to produce novel compounds (Kunnari et al., 1999; McDaniel et al., 1993; 
Miyamoto et al., 2000; Remsing et al., 2003), to generate more efficient production 
mutant strains (Lomovskaya et al., 1999) and to replace chemical synthesis methods 
(Madduri et al., 1998). However, systematic methods to efficiently harness the 
naturally existing genetic potential still remain to be elucidated.  To supplement gene-
level research in understanding the biosynthetic pathways, research has expanded to 
different fields of enzyme study, in vitro protein chemistry, high-resolution structural 




Figure 3. Simplified representation of some common steps in anthracycline and angucycline biosynthesis. 
R=CH3 in nogalamycin pathway and typical angucycline biosynthetic routes. R=CH2CH3 in 
aclacinomycin pathway. The intermediates NAME and UWM6 are the substrates used in this study. 
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1.4 Tailoring enzyme in vitro structure/function analysis 
1.4.1 Goals of enzyme research  
One of the primary aims of molecular-level enzyme research is to provide a detailed 
understanding of the mechanisms and interactions behind observed biological functions. 
The in vitro approach enables the isolation of individual biosynthetic events, and 
investigation of enzyme biochemical properties and catalytic steps in a defined 
environment. Together with high-resolution structural information and mutational 
analysis, it is a powerful tool to study enzyme mechanisms and interactions at atomic 
level. One of the standing goals is to combine the knowledge of different disciplines to 
construct models for prediction and design, as in this case, to rationalize pathway 
modification and combinatorial biosynthesis. Structure/function information has already 
been applied to predict enzyme substrate specificity (Yadav et al., 2003) and to pre-
screen functional ligands from a pool of chemically diverse molecules (Kim et al., 2007). 
It can also be used to simulate the native catalytic reaction whenever the biological 
substrate is not available for biochemical studies (Korman et al., 2008) or to evaluate the 
roles of specific residues in the active site against a putative function (Ames et al., 2008).  
1.4.2 Enzyme research, past and present  
The enzymological era of polyketide biosynthesis research began in the 1990’s when the 
first crude cell extract fractionations and in vitro characterizations were carried out. 
Amongst the first post-PKS polyketide tailoring enzymes to be isolated and studied was 
carminomycin 4-O-methyltransferase DnrK (then called CMT or COMT). It was partially 
purified from the wild type producer Streptomyces sp. strain C5 by ammonium sulphate 
precipitation and DEAE-Sepharose fractionation (Connors & Strohl, 1993). The efficiency 
of protein recovery procedures became more effective by heterologous over-expression 
systems in different Streptomyces species and E. coli, which were adapted to purify DnrK 
further (Madduri et al., 1993) and in production of enzymes such as cytochrome P-450 
DoxA from the doxorubicin biosynthetic pathway (Walczak et al., 1999). The purification 
procedures were further enhanced by the use of specific affinity tags in protein extraction, 
which provided a routine means of purifying protein preparates to near homogeneity. This 
paved the way for more elaborate in vitro characterization methods and protein crystal 
structure determination. The first crystal structure of an aromatic polyketide tailoring 
enzyme, oxygenase Act VA-Orf6 (S. coelicolor, actinorhodin biosynthesis) was solved in 
2003 (Sciara et al., 2003). It was soon followed by the high-resolution structures of 
aclacinomycin methyl esterase RdmC (Jansson et al., 2003b) and aclacinomycin-10-
hydroxylase RdmB (Jansson et al., 2003a) (S. purpurascens rhodomycin biosynthesis) later 
the same year. Despite the extensive research around the aromatic polyketide biosynthesis, 
only around a dozen tailoring enzyme structures had been deposited in Protein Data Bank 
(PDB; www.rcsb.org) by the beginning of 2008, and only about half with a bound ligand in 
the active site. The enzymes discussed in this work are listed in Table 1. Numerous 
publications have focused on the enzymology of the earlier biosynthetic PKS steps (most 
recently reviewed by Hertweck et al. (2007) and Metsä-Ketelä et al. (2007)) but they are 
not discussed in the scope of this work.  
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Table 1. Type II aromatic polyketide tailoring enzymes (including fourth-ring cyclases) with resolved 
crystal structures. 
Enzyme name 
(PDB accession code) 





aklavinone-1-hydroxylase S. galilaeus;  
cinerubin  









Sciara et al., 2003 
AknH  
(2f98;2f99) 












Alexeev et al., 2007 
CabE  
(2qa2) 









Jansson et al., 2004 
PgaE  
(2qa1) 














S. purpurascens;  
β-rhodomycin 
Jansson et al., 2003b 
SnoaL  
(1sjw) 







aklavinone-1-hydroxylase S. nogalater; 
nogalamycin 
Beinker et al., 2006 
TcmI  
(1tuw) 
tetracenomycin F2 cyclase S. glaucescens; 
tetracenomycin 







Mittler et al., 2007 
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2. AIMS OF THE PRESENT STUDY 
This work focuses on the enzymology of Streptomyces secondary metabolism, 
specifically on selected post-PKS tailoring enzymes of type II aromatic polyketides. 
The target enzymes are the homologous polyketide cyclases SnoaL and AknH involved 
in anthracycline biosynthesis (I-III), and PgaE/CabE and PgaM which catalyze 
consecutive reaction steps in angucycline biosynthesis (IV-VI). The specific aims of 
the research were i) to set up preparative and analytical systems to enable the enzyme 
in vitro studies, ii) to verify the catalytic functions of the enzymes, and iii) to 
investigate their molecular-level reaction mechanisms and interactions. 
In a broader sense the aim was to evaluate the functional and mechanistic features of 
these biosynthetic enzymes in general; to see if the enzymes share any common 
characteristics, and to see if and how the genetic plasticity of Streptomyces genome is 
reflected in the function of individual biosynthetic enzymes. 
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3. MATERIALS AND METHODS 
General: Here is a brief outline of the most common techniques, materials and 
methods I have used in this study. More comprehensive descriptions are presented in 
the corresponding original publications I-VI.  
DNA amplification: The high-fidelity Phusion DNA polymerase (Finnzymes, 
Finland) was used for all PCR amplifications. The reactions were carried out with 3% 
DMSO to facilitate DNA strand separation as instructed by the manufacturer. PCR 
primers were ordered from MWG (Germany) or TAGC Copenhagen (Denmark). All 
final constructs were verified by sequencing.  
Plasmid constructs: The plasmids used in this study were constructed by conventional 
molecular biology techniques (Sambrook et al., 1989) in combination with commercial 
DNA isolation kits (Qiagen GmbH, Germany). The E. coli plasmids were modified 
from a commercial vector pBAD/HisB (Invitrogen, USA) and the final Streptomyces 
plasmids were derivatives of pIJE486 (Ylihonko et al., 1994). The constructs used for 
the production of substrates NAME and UWM6 were pSY15 (Kunnari et al., 1999) 
and pMC6BD (Metsä-Ketelä et al., 2003) respectively. 
Targeted mutagenesis: Due to the high GC content in Streptomyces DNA, many 
commercial mutagenesis kits have been found to be inefficient or unreliable. For this 
reason, all targeted mutagenesis constructs were made using a conventional 2-step 4-
primer PCR method (Higuchi et al., 1988). The method employs specific mismatch 
primers to introduce desired nucleotide substitutions in the amplified genes in two 
successive PCR reaction steps. 
Transformation methods: E. coli transformations were carried out either by 
electroporation or heat-shock transformation of calcium chloride competent cells 
(Ausubel et al., 1994). Streptomyces protoplasts were prepared and transformed as 
instructed in Hopwood et al., 1985.   
Cell lines: The E. coli strain used for the studies was the commercial TOP10 acquired 
from Invitrogen (USA). The Streptomyces host strain used for protein over expression 
and substrate production was S. lividans TK2 (Hopwood et al., 1985).  
Culture conditions: Depending on the specific application, cells were cultured at 
37ºC, 30ºC or at room temperature in volumes ranging from 250ml flask cultures to 5L 
fermentor batches. The E. coli cultures were grown in rich 2xYT (yeast extract / 
tryptone) medium, whereas TSB (tryptic soy broth) medium (Kieser et al., 2000) was 
typically used for the protein over expression in Streptomyces. Enzyme 
selenomethionine derivatives were produced in minimal drop-out medium (Sultana et 
al., 2007). The medium used for substrate production was E1, with or without XAD 
resin as an adsorbent (Ylihonko et al., 1994). 
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Protein purification and analysis: The target enzymes were typically overproduced 
as N-terminal histidine-tag or GST fusion proteins. The enzymes were purified to 
homogeneity in different combinations of specific affinity chromatography, gel 
filtration and anion exchange, using pre-packed commercial Amersham (Amersham 
Biosciences, UK) columns and ÄKTA FPLC (Amersham Biosciences, UK) 
chromatography system. Purity of protein samples was verified by SDS 
electrophoresis. Occasionally, purified proteins/variants were analyzed by protein mass 
spectrometry (TOF MS ES+) to confirm the exact mass. 
Enzyme assays and reaction product analysis: In vitro enzyme reactions were 
carried out in 1ml volume in buffer conditions and concentrations optimized for each 
specific case. The reactions were monitored either kinetically using a UV-Vis 
spectrophotometer, or by qualitative/quantitative HPLC analysis of reaction products 
isolated by organic solvent extraction (chloroform or ethyl acetate). For some 
applications the reactions were coupled to secondary enzymatic conversion steps, 
and/or to analysis by LC-MS or NMR. 
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4. RESULTS AND DISCUSSION 
4.1 Introduction  
This section summarizes the most important findings of the experimental work 
presented in the original publications I-VI. Selected central themes are then discussed 
in a broader context in relation to literature. 
The experimental work was carried out in close co-operation between our research 
team (Antibiotic Biosynthetic Enzymes, Department of Biochemistry and Food 
Chemistry, University of Turku, Finland) and our collaborators (Molecular Structural 
Biology, Department of Medical Biology and Biophysics, Karolinska Institutet, 
Stockholm Sweden). DNA constructs*, heterologous protein expression and 
purification, substrate isolation, activity assays and enzyme functional characterization 
were done in our laboratory. Protein structural studies including crystallization, X-ray 
analysis and structure determination (I-IV) were carried out by our collaborators. 
*with the exception of the SnoaL variant constructs, which were produced by Jishu Wang at Karolinska 
Institutet. 
4.2 Polyketide cyclases SnoaL and AknH in anthracycline 
biosynthesis (original publications I-III) 
4.2.1 Introduction to SnoaL and AknH 
Anthracyclines are amongst the most extensively studied group of type II aromatic 
polyketides. They are derivatives of the tetracyclic 7,8,9,10-tetrahydro-5,12-
naphtacenoquinone structure, and the biologically active species are typically 
(poly)glycosylated at position C7 by deoxysugars and aminodeoxysugars. 
Anthracyclines are best known for their clinical applications in cancer treatment, as 
exemplified by daunorubicin, doxorubicin and epirubicin, which have been used for 
decades in the clinical treatment of various types of solid and hematopoietic tumors. 
Over the years in the search for more effective drugs with less severe side effects, 
thousands of anthracycline derivatives have been found and characterized, and the 
biosynthesis of several model compounds have been elucidated in detail. One of these is 
aclacinomycin A (aclarubicin) (Figure 4) which has been used in medicine, and 
thoroughly studied both for its clinical activities (Karanes et al., 1990; Nitiss et al., 1997; 
Wakabayashi et al., 1980; Wang et al., 2002) and its biosynthesis (Alexeev et al., 2007; 
Jansson et al., 2003b; Jansson et al., 2005; Leimkuhler et al., 2007; Lu et al., 2004; Räty 
et al., 2002a; Räty et al., 2002b). Nogalamycin (Figure 4) is another anthracycline 
antitumor antibiotic, which has been under focus in relation to its mode of action (Box, 
2007; Williams et al., 1990), genetics and biosynthesis (Torkkell et al., 1997; Torkkell et 
al., 2001; Ylihonko et al., 1996). In comparison to typical anthracyclines, nogalamycin is 
characterized by an unusual glycosylation (nogalamine attached to C1 and C2) (Wiley et 
al., 1977) and an opposite C9 configuration (Arora, 1983). 
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Figure 4. Aclacinomycin A and nogalamycin, the products of akn (S. galilaeus) and sno (S. nogalater) 
pathways, respectively. 
SnoaL and AknH are representatives of a group of small aromatic polyketide cyclases, 
which are responsible for closing the last aglycone carbon ring in various anthracycline 
pathways; completing the tetracyclic core for successive pathway-specific tailoring 
reactions (Figure 3). AknH catalyses the conversion on aklanonic acid methyl ester 
(AAME) to aklaviketone in aclacinomycin A biosynthesis in S. galilaeus. SnoaL 
catalyses the corresponding reaction in nogalamycin biosynthesis in S. nogalater, 
converting nogalonic acid methyl ester (NAME) to nogalaviketone in vivo (Torkkell et 
al., 2000). The enzymes are both 144 amino acids in length and 67% identical at the 
amino acid level. They also share substantial sequence similarity with other members 
of the cyclase class such as RdmA (rhodomycin biosynthesis; S. purpurascens) (Niemi 
& Mäntsälä, 1995), DnrD (doxorubicin biosynthesis; S. peucetius) (Kendrew et al., 
1999), and DauD (daunomycin biosynthesis; Streptomyces sp strain C5) (Dickens et 
al., 1995). 
The reactions catalyzed by SnoaL and AknH are of specific interest because they 
determine the stereochemical outcome of the final biosynthesis products. SnoaL has 
been shown to be solely responsible for the unusual C9-S configuration observed in 
ring A of nogalamycin (Torkkell et al., 2000). AknH in turn directs the biosynthesis 
towards AKV the most common precursor of anthracycline-type polyketides with the 
opposite C9-R stereochemistry. As the primary initiative to our enzyme-level study, 
we set out to investigate in vitro the molecular basis behind this enzyme 
stereoselectivity. 
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4.2.2 Proteins and substrate for characterization 
As the initial step of the experimental study, the entire genes encoding for SnoaL and 
AknH were cloned into several modified pBAD/HisB -based plasmid expression 
vectors and verified by sequencing. These vectors were later used as templates for 
active site variant constructs listed in tables 2 and 3. The enzymes were heterologously 
expressed in E. coli as N-terminal histidine-tag fusion proteins (I-III). As an exception, 
due to instability resulting from active site amino acid substitutions, the AknH variants 
were produced as GST (glutathione S-transferase) fusion proteins (III). The 
corresponding non-mutated AknH/GST was prepared in parallel for comparison. The 
optimized soluble recovery yields were typically in the milligram-range per liter 
culture medium. The proteins were purified using different combinations of 
consecutive preparative chromatography steps including affinity chromatography, gel 
filtration and anion exchange. For each preparate, purity and protein size were verified 
by SDS-PAGE electrophoresis, followed by biochemical and/or structural 
characterization. 
The biological substrate for SnoaL, NAME, was provided by Dr. Tero Kunnari for the 
initial experiments, and later produced and purified using a hybrid production strain S. 
argillaceus /pSY15 (Ylihonko et al., 1996). NAME was also used for all AknH 
activity measurements because the natural substrate AAME was unavailable. 
4.2.3 Cyclase reactions in vitro  
Both enzymes were active and shown to convert NAME in vitro (Figure 5). The 
reactions were monitored using a HPLC-based end-point method, either as a decrease of 
the substrate (II) or as an increase of the cyclized product (III). The reactions were 
typically carried out near the saturation limit of the substrate, well above the 
physiological substrate concentrations and above the expected KM value range of the 
enzymes. In these conditions the quantitation of end product formation proved more 
accurate than the comparison of modest changes in integrated substrate peak areas. The 
end product approach also enabled the stereochemical assays described in section 4.2.4.  
The conversion of NAME could also be detected spectrophotometrically as a slight 
increase in absorbance (Δmax at 420nm), but due to small differences in signal 
intensities and resulting poor reproducibility, the method was not useful for 
quantitation (results unpublished). In an attempt to set up a more sensitive kinetic 
assay, we decided to couple the reactions to a secondary enzyme-catalyzed step with a 
potentially higher signal. The idea was to use the consecutive biosynthetic enzymes, 
the 7-ketoreductases SnoaF and AknU (see Figure 3) from the nogalamycin and 
aclacinomycin pathways, respectively. The genes were cloned into expression 
constructs, followed by enzyme production and purification, but the soluble recovery 
yields remained too low for practical use (results unpublished). 
Altogether, kinetic characterization of the cyclases was hindered by the lack of a 
reliable continuous assay and the means of determining the absolute substrate and 
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product concentrations as the molar absorption coefficients were not known. The 
estimated kcat values for the enzymes in the reaction conditions were around 1s-1, with 
roughly approximated KM values in the low micro-molar range. 
NAME and the cyclization products are pure bright yellow in methanol and in the 
aqueous buffers used in the assays. Upon extended incubation the reaction products 
were shown to slowly undergo further conversion into a reddish compound, expectedly 
as a result of spontaneous loss of the C9 hydroxyl group and aromatization (Figure 5). 
The same product was observed in the SnoaL and AknH crystal structure complexes 
(chapter 4.2.5). 
4.2.4 C9 stereochemical assay 
The stereochemically distinct C9-S and C9-R cyclization products of SnoaL and AknH 
could not be differentiated based on their UV-Vis spectra or separated in conventional 
reverse phase HPLC. However, we demonstrated that the two products could be 
distinguished from one another in a coupled enzymatic assay with a stereospecific 
hydroxylase RdmE (aklavinone-11-hydroxylase) (Niemi et al., 1999) in vitro. RdmE 
was shown to exclusively use the C9-R stereoisomer as a substrate, leaving the C9-S 
product unreacted (Figure 5). The hydroxylated product analog could then be separated 
by HPLC from the initial cyclization products and quantitated to monitor the relative 
amount of each form present (Figure 2 in III). As anticipated, AknH produced 
exclusively the C9-R stereoisomer (auraviketone) whereas SnoaL only produced the 
C9-S form (nogalaviketone). 
 
Figure 5. The in vitro cyclase reactions of SnoaL and AknH with NAME, coupled to RdmE-catalyzed 
hydroxylation. Both cyclase products also may undergo slow spontaneous dehydration leading to the loss 
of C9 stereochemistry.   
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4.2.5 Structures of SnoaL and AknH 
As the first representative of this family of homologous polyketide cyclases, the 3D X-
ray crystal structure of SnoaL was resolved at 1.35Å resolution (PDB accession code 
1sjw) (I-II). The structure was acquired using single isomorphous replacement (SIR) 
with uranium derivative anomalous scattering. SnoaL was crystallized in the presence 
of the NAME substrate, and the electron density clearly revealed a bound ligand in the 
active site. The X-ray crystal structure of AknH (PDB accession code 2f98) was 
resolved by molecular replacement using the SnoaL structure as a template (III). The 
AknH structure was determined in complex with two different ligands, derivatives of 
NAME and AKV at resolution 2.1Å and 1.9Å respectively.  
Structural analysis revealed that SnoaL (Figure 6) and AknH belong to the superfamily 
of  α+ß barrels, and are representatives of the scytalone dehydratase fold (Lundqvist et 
al., 1994). The two enzymes are very similar in their overall tertiary and quaternary 
structures. Both polypeptides fold into a single domain which consists of five-stranded 
mixed ß-sheet, two α-helices and two 310-helices (Figure 3 in II; Figure 3a in III). 
These regular secondary structure elements form a distorted α+ß barrel which encloses 
a large hydrophobic active site cavity. Analysis suggests that the native quaternary 
structure of the proteins is a tetramer composed of a pair of homodimeric subunits 
(Figure 5 in II; Figure 3b in III). The quaternary structures are stabilized by a network 
of hydrogen bonds and expected to undergo a conformational change upon substrate 
binding and product release. The main structural differences between the SnoaL and 
AknH reside in the loop region between helices H3 and H4 (residues 40-43) and at the 
C-terminal end (residues 135-141). 
In both cyclases amino acid residues from nearly all the regular secondary structural 
elements line the substrate binding site, with most of the hydrophobic residues 
arranged in the vicinity of the ring A atoms which participate in the reaction. Although 
the observed ligands in the structure complexes had undergone enzymatic and/or 
spontaneous chemical changes, the orientations of the SnoaL/NAME and AknH/AKV 
derivatives were expected to resemble those in the native productive Michaelis’ 
complexes (Figure 7 in II; Figure 6 in III). In both cases the main enzyme-ligand 
interactions were van der Waals forces and hydrophobic contacts. In the SnoaL 
complex the only direct hydrogen bond was observed between the amide group of 
Gln105 and C14 carbonyl oxygen of the ligand. Sequence comparison revealed that 
this glutamine residue is conserved in the known homologs of the cyclase family. Also 
in AknH the Gln105 was shown to participate in a network of hydrogen bonds which 
interacts with the bound ligand. Another invariant residue found in the active site 
cavities in the proximity of the reacting C9 of both enzymes was Asp121, which was 
expected to have a role in the catalysis. Based on the structural information several 
active site variants were prepared and characterized (Table 2) to clarify the reaction 
mechanism employed by the cyclases.  
 




Figure 6. Representation of the SnoaL monomer X-ray crystal structure with a bound ligand. The key 
active site residues under study are shown in the close-up. The ligand is a cyclized product derivative, 
which has lost the C9 hydroxyl substituent in unspecific dehydration, resulting in ring A aromatization and 
loss of C9 stereochemistry.  
4.2.6 Cyclase reaction mechanism 
In chemical terms the reaction catalysed by SnoaL and AknH is an intramolecular aldol 
condenzation. This reaction is initiated by proton abstraction at the reacting carbon, 
resulting in a carbanion/enol(ate) intermediate. Typically this step is facilitated by 
stabilizing the intermediate either through covalent Schiff base formation (class I 
aldolases) or by using metal ion stabilization (class II aldolases). However, the cyclases 
SnoaL and AknH do not have either an appropriately positioned lysine residue or a 
metal ion cofactor required for these mechanisms. Instead, the catalysis may proceed 
through an unusual aspartate-driven acid-base mechanism. According to the model, the 
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reaction is initiated by the removal of the C10 proton by the invariant residue Asp121 
(Figure 7; step 1). In addition to the favorable orientation of this residue, its role is 
emphasized by the fact that the point mutation Asp121Ala either completely 
inactivates the enzyme (SnoaL) or seriously impaires the catalytic activity (0.2% 
residual activity in AknH) (Table 2). In contrast to the classical aldolases, the essential 
intermediate stabilization is proposedly brought about by π electron delocalization over 
the extended aglycone ring system (discussed in chapter 4.5.3). Additional yet less 
significant stabilization is provided by hydrogen bond formation between C14 carbonyl 
oxygen and the invariant residue Gln105. In accordance, the point mutation Gln105Ala 
moderately decreased the relative enzyme activities of SnoaL (15%) and AknH (6%). 
A comparable effect in AknH resulted from the substitution of the conserved residue 
His107, which also participates in the stabilizing hydrogen bond network. The 
subsequent step in the catalysis is an intermolecular nucleophilic attack of the 
carbanion intermediate on the C9, which leads to ring A formation (Figure 7; step 2). 
To complete the reaction cycle, the remaining oxyanion/alcoholate at C9 is protonated, 
proposedly by Asp121 in SnoaL, or by a catalytic water observed in the crystal 
structure in AknH (Figure 7; step 3).  
Table 2. Relative activities of SnoaL and AknH active site variants in comparison to the corresponding 
non-mutated species.  
Cyclase Point mutation Variant relative activity (%) 
vs. wild type 
SnoaL Asp121Ala no detectable activity 
SnoaL Gln105Ala 15 
AknH Asp121Ala 0.2 
AknH Gln105Ala 6 
AknH His107Ala 2 
 
4.2.7 Cyclase stereochemical determinants 
SnoaL and AknH are highly similar in primary structure, 3D fold and catalytic 
mechanism, yet when provided with the same substrate, the reaction products differ in 
the stereochemistries of C9 of the ring A. The opposite conformations must be 
determined by structural differences between the active sites, and apparently in part, by 
a hydrophobic area surrounding one side of the reacting atoms. The topology of the 
SnoaL-ligand complex implicates that the C9-S product is formed as a result of 
nucleophilic attack on the re face of the C9 aldehyde (Figure 7; step 2). This reaction is 
energetically favored because it orients the forming alcoholate towards the protonated 
Asp121, and away from the substantially hydrophobic environment of the opposite 
face. Intriguingly, the distribution of hydrophobicity around the forming ring A is 
different in cyclases which produce the C9-R stereoisomer, and as in AknH, the 
nucleophilic attack takes place on the si face (Figure 7; step 2). Sequence analysis 
shows that these enzymes have a conserved residue Tyr15 instead of a highly nonpolar 
Phe15 located within a van der Waals distance from C9 of the product in SnoaL. The 
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substitution Phe15Tyr in SnoaL, however, did not alter the reaction stereoselectivity. In 
contrast, the corresponding reverse substitution Tyr15Phe in AknH resulted in a partial 
loss of specificity and formation of the unnatural C9-S product (20% of the total yield) 
(Figure 2c in III). Further decrease of polarity in the hydrophobic area near the Asp121 
in AknH was achieved by a second substitution Asn51Leu. This additional mutation 
Asn51Leu with Tyr15Phe completely abolished AknH stereoselectivity, resulting in 
the formation of a racemic mixture of C9-S and C9-R stereoisomers (50% each) 
(Figure 2d in III). The remaining structural factors which determine the absolute 
stereochemistries were left unindentified, but may involve the loop residues between 
helices H3 and H4 or the C-terminal amino region (see Figure 6) where the most 
significant structural differences were observed. Despite the fact that complete reversal 
of stereochemistries was not achieved, this work demonstrated that molecular-level 
information on enzyme structure and function may enable enzyme modification to 
specifically alter enzyme enantioselectivity by targeted mutagenesis. 
Table 3. Stereoselectivity and relative activities of SnoaL and AknH active site variants in comparison to 
the corresponding wild type species. 




SnoaL Phe15Tyr 5 C9-S / no change in 
stereochemistry 
AknH Tyr15Phe 45 ~20% change from C9-R 
to C9-S 
AknH Tyr15Phe & Asn51Leu 20 ~50% change from C9-R 
to C9-S 
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Figure 7. The proposed cyclase catalytic mechanism and determination of stereoselectivity in SnoaL and 
AknH (intermediate aromatic resonance stabilization not shown). 
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4.3 Oxygenation reactions in angucycline biosynthesis (original 
publications IV-VI) 
4.3.1 Background to angucycline research 
Angucyclines are a distinct group of natural aromatic polyketides produced by various 
Streptomyces species (Rohr & Thiericke, 1992). They are closely related to 
anthracyclines, and characterized by the angular shape of the tetracyclic 
benz[a]anthracene ring frame. The first angucycline structures were described already 
in the mid 60’s (Dann et al., 1965), yet today only a little over one hundred different 
structures are known. DNA fingerprinting studies have indicated that angucycline 
clusters may be much more common in nature than this number of discovered 
compounds implies (Metsä-Ketelä et al., 2002). Angucyclines have been shown to 
possess a variety of bioactive properties (Abdelfattah et al., 2003; Antal et al., 2005; 
Bringmann et al., 2005; Korynevska et al., 2007), but so far they have not been used 
for any direct medical applications. 
The most extensively characterized representatives of the angucycline family include 
landomycin (Henkel et al., 1990), urdamycin (Drautz et al., 1986) (Figure 8) and 
jadomycin (Ayer et al., 1991), for which many of the biosynthetic steps have been 
described in detail. The biosynthesis follows the typical steps of type II polyketide 
assembly, diverging on the angucycline pathway as a result of specific cyclase which 
orients the forming 4th ring in an angled position (Metsä-Ketelä et al., 2003) (Figure 3). 
There has been certain ambiguity, however, in regard to some of the subsequent post-
PKS tailoring steps. Specifically, the successive oxygenation steps which follow the 
aglycone 4th ring cyclization are not yet fully understood, and due to difficulties in 
determining the catalytic events involved in vivo, the reaction cascades have sometimes 
been described as “biosynthetic black boxes” (Rix et al., 2005). The primary initiative 
to this experimental work was to study these biosynthetic steps by isolating the 
individual enzyme-catalyzed reactions in selected model pathways in vitro. The aim 
was to confirm the catalytic functions of specific enzymes (PgaE, PgaM and CabE), 
and to study the mechanisms involved. 
The target enzymes PgaE and PgaM derive from partial cryptic angucycline-type gene 
cluster pga from Streptomyces sp. PGA61 (Metsä-Ketelä et al., 2004), whereas CabE 
originates from the related cab cluster from Streptomyces sp. HO21 (Palmu & Kunnari, 
2002) (Figure 2). The clusters were initially detected in a genetic screen specific for 
type II aromatic polyketide PKS regions (Metsä-Ketelä et al., 1999), cloned and 
reconstructed for in vivo gene function analysis (Palmu et al., 2007). PgaE and CabE 
are homologous to flavin-dependent hydroxylases and mono-oxygenases, and,  based 
on in vivo studies, they were expected to participate in UWM6 C12 hydroxylation. 
Sequence analysis implicates that PgaM is a two-domain protein which consists of a N-
terminal region homologous to flavoprotein mono-oxygenases fused to C-terminal 
domain homologous to short-chain alcohol reductases/dehydrogenases (SDR). These 
two putative functional domains have been suggested to participate in the angucycline 
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core C12b hydroxylation and 2,3-dehydration, respectively (Palmu et al., 2007). There 
has been, however, uncertainty about the reaction sequence and the chemical nature of 
the true reaction product. 
 
Figure 8. Rabelomycin, a common intermediate and/or shunt product observed in various angucycline 
pathways. Urdamycin and landomycin are products of urd and lan pathways, repectively. The final 
products of the pga and cab pathways are unknown. 
4.3.2 Enzymes and substrate for the studies 
The entire open reading frames encoding for PgaE, CabE and PgaM were cloned into 
various plasmid expression constructs and verified by sequencing. The PgaE construct 
was later used as a template for several active site variants listed in table 4. PgaE and 
CabE were expressed as  N-terminal polyhistidine tag fusion proteins in E. coli TOP10. 
Due to low recovery yields in E. coli, PgaM was typically produced in a corresponding 
construct in S. lividans TK24. The enzymes were purified using combinations of 
chromatographic techniques including nickel affinity chromatrography and preparative 
gel filtration, followed by analytical SDS-PAGE chromatography to confirm purity. 
The purified enzymes remained active in storage and were used for structural and 
biochemical characterization. 
The substrate UWM6 was produced and purified from Streptomyces TK24/pMC6BD 
(Metsä-Ketelä et al., 2003) a construct which harbors all the biosynthetic genes of the 
pathway prior to the gene encoding for PgaE. Purified UWM6 was apparently stable 
and did not show signs of degradation or spontaneous conversion when stored 
solubilized in methanol. 
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4.3.3 Sequence of reactions catalyzed by PgaE and PgaM; formation of 
gaudimycin C  
PgaE and PgaM were shown to catalyse a series of consecutive reactions in vitro (VI). 
The first step, conversion of the biosynthetic intermediate UWM6, was catalysed by 
PgaE. This reaction could be directly monitored as consumption of UWM6, either 
spectrophotometrically at the substrate absorption maximum or by using quantitative 
HPLC-based end-point system optimized for the purpose (Figure 2 in VI). The 
PgaE/UWM6 conversion product, however, could not be isolated or detected. In 
contrast to the corresponding reaction in vivo which had been previously shown to 
yield rabelomycin (Figure 8) (Palmu et al., 2007), the reaction in vitro invariably 
resulted in product degradation. This was observed in HPLC as the formation of 
multiple unstable minor products (Figure 3 in VI). The degradation could be avoided 
by coupling the PgaE reaction to the next biosynthetic steps catalysed by PgaM. 
Incubation of PgaM together with PgaE and UWM6 resulted in the formation of a new 
stable product which could be extracted for detailed study. The coupled reaction was 
shown to be highly dependent on simultaneous presence of the two enzymes, and 
sensitive to variations in the relative enzyme concentrations, observed as intermediate 
product breakdown in unoptimal reaction conditions (Figure 4 in VI). Although the 
results implicated that the two enzymes may require direct contact with eachother to 
carry out the sequential reactions, physical interaction or complex formation could not 
be observed. 
LC-MS analysis revealed that the product of the coupled PgaE/PgaM reaction with 
UWM6 had a mass (356m/z), 14amu higher than that of UWM6 (342m/z). To 
determine the chemical changes involved, we set off to investigate the product 
structure by NMR spectroscopy. Successive preparative-scale in vitro enzyme 
reactions followed by consecutive purification steps were carried out to produce 
sufficient material for the analysis. Eventually, a complete NMR structure of the 
compound was resolved (Table 2 in VI), confirming the compound as a novel 
angucycline intermediate. The structure was different from the corresponding in vivo 
product of the homologous cab pathway, gaudimycin B, only in the stereochemical 
orientation of the C6-OH substituent. Interestingly, it was also different from the 
equivalent in vivo pga product, gaudimycin A, in which the C6 hydroxyl group was 
completely missing. Consequently, the in vitro product was named gaudimycin C 
(Figure 9). The structure of gaudimycin C allowed us to deduce the chemical steps of 
the PgaE/PgaM reaction cascade. Significantly, it included hydroxylation at positions 
C12 and C12b, C7,12- quinone formation, C2,3-dehydration and stereospecific 
ketoreduction at C6.  
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Figure 9. In vitro reaction of PgaE and PgaM with UWM6 leads to the formation of gaudimycin C. The 
corresponding in vivo reaction in heterologous host S. lividans TL24 yields gaudimycin A (6-dehydroxy 
gaudimycin C), whereas the reactions catalyzed by homologous CabE and CabM produce gaudimycin B 
(C6 stereoisomer of gaudimycin C). 
4.3.4 PgaE functions as UWM6 C12 hydroxylase in vitro 
The first direct evidence of PgaE function and mechanism was the requirement for 
oxygen; the conversion of UWM6 by PgaE was inhibited in anaerobic conditions in 
vitro. In parallel, the reaction was dependent on equimolar input of NADPH as 
expected based on homology with flavoprotein hydroxylases and mono-oxygeneses. 
Direct confirmation of hydroxyl group addition by intermediate structure analysis was 
not possible because of the instability of the PgaE/UWM6 reaction product. This was, 
however, verified indirectly by LC-MS 18O2  incorporation analysis of the coupled 
PgaE/PgaM reaction. It revealed that one of the two newly-attached oxygen atoms in 
gaudimycin C originated from O2 (Table 1 in VI), in agreement with the expected 
hydroxylase function and the observed dependence for molecular oxygen. 
Based on the structures of gaudimycin C and the corresponding in vivo (shunt) product 
rabelomycin, the target position for the hydroxylation was deduced to be C12. 
Apparently, the resulting UWM6 7,12-dihydroquinone is highly reactive, and 
spontaneously undergoes further reactions leading to breakdown in vitro, unless 
coupled to the subsequent enzyme-stabilized steps. The oxidation events which lead to 
the formation of the observed 7,12-quinone are not yet clearly understood, but may 
take place non-enzymatically if the rest of the molecule is correctly stabilized. 
Mechanistic features of the PgaE reaction were investigated in a structure based 
enzyme study (IV) presented in the following chapters.  
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4.3.5 PgaE/CabE crystal structure overview  
The 3D structures PgaE and its homolog CabE were determined and studied in relation 
to characterized proteins similar in fold and function to understand the molecular basis 
of the catalysis (IV). The X-ray crystal structure of PgaE (PDB accession code 2qa1) 
was determined at 1.8Å resolution with multiple anomalous diffraction using 
selenomethionine derivative for phasing. The structure of CabE (PDB accession code 
2qa2) was solved by molecular replacement at 2.7Å resolution using the PgaE structure 
as a template. Ligand-bound complexes were not obtained despite attempts to 
incorporate several different compounds into the crystals by co-crystallization and 
soaking.  
The 3D structure analysis revealed PgaE and CabE  to be highly similar members of 
para-hydroxybenzoate hydroxylase (pHBH) fold family (Figure 3 in IV). Three 
previously characterized members are flavin-dependent aromatic hydroxylases pHBH 
(Weijer et al., 1983; Wierenga et al., 1979), MHBH (Hiromoto et al., 2006) and PHHY 
(Enroth et al., 1998) which resemble the target enzymes in the overall fold, although 
primary sequence similarity is relatively low. The PgaE (Figure 10) and CabE subunits 
consist of three distinct domains. A large FAD binding domain, with the highest 
similarity with the structure homologs, is intervened in the primary structure by a 
smaller middle domain. The putative enzyme active site cavity is located at the 
interface of these two domains. The active site is hydrophobic in character and 
significantly large in comparison to the other members of the fold family, as expected 
by the relatively large size of the aromatic polyketide substrate. Most residues lining 
the active site cavity are conserved between the two proteins. The third, C-terminal, 
domain is of yet unknown function. It has a thioredoxin fold yet the putative catalytic 
residues have not been conserved. The native quaternary structure is a dimer formed 
via interactions at the FAD binding domain interface. The quaternary structures 
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Figure 10. X-ray crystal structure of PgaE monomer showing the relative orientation of the three domains. 
4.3.6 PgaE/CabE mutagenesis studies and mechanistic implications 
The members of the fold family employ a complex catalytic mechanism in which the 
NADPH/FAD/O2 redox cycle is coupled with conformational change to bring about 
substrate hydroxylation. This involves a transition between the so-called in-
conformation in which the FAD isoalloxazine ring is tilted towards the substrate in the 
active site, and the out-conformation which allows contact between FAD and the co-
substrate NADPH. The cycle is initiated when substrate binding triggers the transition 
towards the out-conformation, followed by the reduction of FAD by NADPH 
(reductive half-reaction). The resulting FADH- anion is attracted by the positive 
electrostatic field of the active site, which induces the switch back to the in-
conformation. In the subsequent step the reduced flavin reacts with molecular oxygen 
(oxidative half-reaction), which eventually leads to flavin hydroperoxide formation and 
substrate hydroxylation. Structural analysis suggests that this model also applies for 
PgaE and CabE. The bound FAD is well defined in both crystal structures in the in-
conformation. In one of the putative productive substrate binding modes found by 
molecular docking with PgaE, the FAD C4a which participates in oxygen activation is 
positioned in the proximity of substrate C12, the target for hydroxylation. Based on the 
structural data and comparison with the characterized homologs, several different PgaE 
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active site variants (His73Ala, Lys92Gln, Pro282Ser and Asn289Asp) were designed 
and prepared for biochemical analysis to study the catalytic mechanisms involved. 
A key step in the pHBH redox cycle is an enzyme-catalyzed substrate deprotonation, 
which contributes to the transition from the in- to the out-conformation. In the modeled 
CabE and PgaE enzyme-substrate complexes there are only two suitably positioned 
residues, His73 and Lys92, which could potentially act as such catalytic bases. In 
targeted mutagenesis studies, however, the substitutions His73Ala and Lys92Gln were 
shown not to reduce the enzyme activity (Table 4). Another residue affiliated with the 
switch to the out-conformation is the strictly conserved residue corresponding to 
Pro282 in PgaE and CabE, which has been proposed to trigger the FAD movement as a 
response to substrate binding and deprotonation in pHBH. Substitution of the residue 
by serine has been reported to seriously impair the activity of pHBH (Palfey et al., 
2002) and PHHY (Xu et al., 2002), but for PgaE the mutation (Pro282Ser) did not 
have an equivalent effect (Table 4). Taken together, the results imply that the enzyme 
i) may not require specific residues for substrate deprotonation, and ii) employs some 
alternative mechanism independent of interactions between Pro282 and the substrate to 
facilitate the FAD in/out conformational transition. Interestingly, two of the variants 
(His73Ala and Pro282Ser) were shown to have a somewhat increased catalytic activity 
in comparison to the wild type enzyme. As the measurements were carried out in 
substrate concentrations which are substantially higher than expected for physiological 
conditions, the changes are assumed to be due to kcat rather than KM. This suggests that 
these substitutions somehow decrease the energy barrier required to overcome to 
induce the conformational change, perhaps via favorable alterations in the electrostatic 
environment of the FAD binding site. Another residue conserved in the fold family is 
an asparagine (Asn289 in PgaE and CabE) located in the proximity of FAD 
isoalloxazine ring in the out-conformation. It is expected to have a role in aligning 
FAD in a favorable orientation for the reduction by NADPH. Substitution of the 
residue by a negatively charged aspartate (Asn289Asp) resulted in the drop of relative 
enzyme activity down to 1% in PgaE (Table 4), an effect equivalent to that reported for 
pHBH (Palfey et al., 1994). The substitution apparently prevents the formation of a 
hydrogen bond between the residue 289 and the carbonyl oxygen of the cofactor, and 
at the same time destabilizes the nascent negative charge formed on FAD upon 
reduction. 
Table 4. The specific activities of PgaE active site variants in relation to the wild type enzyme. 
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4.3.7 PgaM is a multifunctional oxygenase/reductase  
Functional characterization of PgaM was complicated by the fact that stable substrate 
was not available, and the measurements had to be carried out in tandem with the PgaE 
reaction (VI). In addition, the number of sequential chemical changes in one reaction 
cycle had been found to be unusually high as seen in the structure of gaudimycin C, yet 
none of the intermediate products were sufficiently stable for isolation and analysis. 
Multiplicity of the reactions could be explained at least in part by the dipartite structure 
of PgaM, which contains two distinct putative functional domains (V; described in 
chapter 4.3.8). Although the sequential reactions could not be separated from each 
other, the results were consistent with earlier reports, supporting the role of the C-
terminal SDR domain as a 2,3-dehydratase, and the N-terminal domain as a C12b 
hydroxylase (VI).  
Perhaps as the most intriguing mechanistic finding, LC-MS analysis of reactions 
carried out in H218O unambiguously demonstrated that the C12b oxygen attached to 
gaudimycin C derives from water, not air (Table I in VI). This is in disagreement with 
the reactions in homologous pathways (Udvarnoki et al., 1992), and inconsistent with 
any previously proposed reaction mechanism for the C12b hydroxylation  (Udvarnoki 
et al., 1992; Rix et al., 2003). The experiments also confirmed several things about the 
remaining reaction step left unaccounted for, the C6 ketoreduction. First, the 
ketoreduction was shown to be stereospecific, and to yield a product which differs 
from the corresponding cab product in the orientation of the C6 hydroxyl substituent. 
Second, this hydroxyl group has been lost in the equivalent in vivo product gaudimycin 
A most likely as a result of endogenous dehydration by the host organism S. lividans 
TK24. In addition, all C12b-hydroxylated 12,7-quinone angucycline structures we 
found in on-line database structure searches had undergone ketoreduction at C6, 
suggesting that these two steps may somehow be mechanistically linked. 
The observations led us to propose a reaction mechanism to explain the role of PgaM 
oxygenase domain in C12b hydroxylation and C6 ketoreduction in gaudimycin C 
biosynthesis (Figure 11). The mechanism combines the central concepts of reactive 
quinone methide (QM) intermediate formation observed for related anthracycline 
structures (Freccero, 2004), and a mechanism earlier described for an unrelated group 
of FAD-dependent hydroxylases involved in toxic phenol/benzo compound 
degradation (Cunane et al., 2000; Fraaije & van Berkel, 1997; Hopper & Cottrell, 
2003). The proposed reaction involves the generation of an angucycline QM 
intermediate, which leads to enzyme-stabilized incorporation of oxygen at C12b from a 
molecule of H2O, accompanied by a mechanistically-coupled stereospecific 
ketoreduction at C6. Due to the presence of numerous simultaneous reactions, 
verification of the model by kinetic means has not been possible. However, enzyme 
structural information, together with detailed understanding of the FAD redox cycle in 
the future may allow us to examine and adjust the model further. 
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Figure 11. Presented model for PgaE and PgaM reactions (VI) 
4.3.8 PgaM; genetic organization and quaternary complex 
Besides the unexpected catalytic features associated with PgaM, the enzyme also has a 
distinct quaternary structure. The gene encoding for PgaM was found to exhibit an 
unusual DNA-level organization, which leads to the formation of two different 
translational products and their association in a non-covalent complex (V).   
The gene PgaM has evolved as a consequence of a fusion between two consecutive 
ancestral reading frames. The stop codon at the end of the first gene (encoding for a 
FAD-dependent flavoprotein oxygenase; denoted as oxygenase) has been inactivated 
by a point mutation, while the start codon and Shine Dalgarno sequence in front of the 
downstream gene (encoding for a short-chain alcohol dehydrogenase/reductase; 
denoted as reductase) have remained intact. As a result, PgaM is expressed as a full-
length oxygenase/reductase fusion, and as a separate reductase identical to the C-
terminal domain in vitro (see Figure 2 in V). The two co-expressed forms associate 
into a native PgaM heterocomplex, which appears to have a structural role in the fusion 
enzyme stability. If isolated from one another, the solubility of each subunit is 
significantly decreased. The full-length form of PgaM alone was shown to retain the 
native enzyme activity (Figure 5 in V), suggesting that the separate reductase does not 
have a direct catalytic role. It however, seemed to have an effect on the PgaM FAD 
oxidation state (Figure 6 in V), yet the biological significance of this remains unclear. 
Based on the observations we proposed a quaternary complex model for PgaM, which 
explains the stability-related behavior of the protein in vitro (Figure 4 in V). According 
to the model, the separate reductase fragment is required to seal off the C-terminal end 
of the full-length protein to prevent PgaM oligomerization. 
Sequence comparison between different biosynthetic routes reveals three alternative 
native forms of homologous systems (Table 1 in V), which represent successive stages 
of mechanistic adaptation in parallel angucycline pathways. In the ancestral form of the 
pathway the two genes are translated separately as independent functional units, as in 
simocyclinone (Trefzer et al., 2002) pathway. PgaM represents the following genetic 
Results and Discussion 
35 
variation after the loss of the intervening stop codon, an organization also found in 
landomycin (Zhu et al., 2005) and urdamycin (Rix et al., 2003) pathways. Presumably 
the most recently developed system is found in the auricin pathway (Novakova et al., 
2002) where the reductase start codon and ribosomal binding site have been lost, and 
apparently the corresponding protein is expressed exclusively in the fusion form.  
4.4 Enzyme stereoselectivity and stereospecificity  
Stereochemistry is an important concept in natural product research, which tightly 
connects the disciplines of medical research and enzymology. Enzyme-catalyzed 
reactions specify the overall stereochemical structure of biosynthetic products, which in 
turn determines their biological properties, interactions with target receptor molecules, 
binding sites and enzymes (Kulig et al., 2004; Lu, 2007). In relation to the present work, 
this is exemplified by the effect of C9 stereochemistry on the pharmacological properties 
of aclarubicin and nogalamycin (Arora, 1983), the respective products of the akn and sno 
pathways, or the difference in C4’ stereochemistry between epirubicin and doxorubicin 
(Jain et al., 1985; Weiss et al., 1986). 
The stereochemistry of aromatic polyketide compounds is defined in various 
stereoselective enzymatic cyclization, oxidation and ketoreduction steps, which give 
rise to pathway-specific chiral centers on the aglycone ring frame. Opposite 
stereochemical enzyme systems are found in parallel biosynthetic routes, and represent 
an important structural element in natural product diversity. In addition to SnoaL and 
AknH which define the above-mentioned C9 stereochemistry in nogalamycin and 
aclacinomycin biosynthesis (III; Torkkell et al., 2000), PgaM and its homolog CabM 
are responsible for the opposite C6 configurations in angucycline biosynthesis (VI; 
Palmu et al., 2007). In analogy, the orientation of C3 substituent in dihydrogranaticin 
and medermycin biosynthesis is determined by gra-ORF5/6 (Taguchi et al., 2001) and 
med-ORF12 (Li et al., 2005), homologs of actVI-ORF1 ketoreductase in actinorhodin 
biosynthesis, respectively. The stereoselective properties appear to be, at least in some 
cases, specified by a relatively small number of residues. As a result, detailed 
understanding of the interactions may enable targeted enzyme modification towards a 
favoured stereochemical outcome (III; Nakajima et al., 1998; Nakajima et al., 1999). 
In parallel to the end product stereoselectivity, many enzymes are stereospecific 
towards a certain chiral form of the substrate (cf. substrate specificity; chapter 4.5.2). 
Consequently, the stereochemical structure may have a profound effect on the 
compatibility between consecutive biosynthetic steps, but at present, the influence of 
compound structure on possible steric or chemical constraints cannot be easily 
determined without experimental case-studies. RdmE, for example, was shown to 
hydroxylate only the C9-R cyclization product of NAME in vitro, whereas the opposite 
C9-S isoform was left completely unreacted (III). In analogy, the C6 hydroxyl 
substituent of the PgaM reaction product was lost as a result of endogenous 
dehydroxylation in vivo, yet on the opposite stereoisomer of the cab pathway retained 
the corresponding OH group in equivalent conditions (VI; Palmu et al., 2007). In other 
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cases, chirality may have no evident impact on enzyme function, as exemplified by 
late-stage tailoring enzymes in doxorubicin biosynthesis, which have been reported to 
be unaffected by the change in substrate C4’ stereochemistry (Madduri et al., 1998). 
Streospecificity is fundamentally determined by the same physicochemical parameters 
as substrate specificity in general, discussed in chapter 4.5.2. 
4.5 Common enzymatic themes and repeated phenomena 
4.5.1 Introduction: Enzyme-level flexibility 
Secondary metabolism pathways are relatively susceptible to changes, because i) 
mutations are not expected to cause acute impairment of essential cellular functions as 
in primary metabolism which stringently regulates growth and development, and ii ) 
alteration increases the potential for chemical diversity which may (in simplified 
terms) lead to selective advantage. This has steered the evolution of the secondary 
metabolism pathways, and can be seen as certain "developmental freedom" at different 
organizational levels. Enzyme-level studies of type II aromatic polyketide pathways 
have provided evidence of various common characteristics which support this concept, 
although due to insufficient reference material, generalizations are difficult to make.  
In context with this work, the following chapters summarize some related themes 
associated with the enzymes. These include, specifically, determinants of substrate 
specificity, and enzyme mechanistic evolution. 
 4.5.2 Relaxed enzyme substrate specificity  
Enzymes involved in different secondary metabolism pathways have been suggested to 
share a common characteristic of relaxed (or broad) substrate specificity, an ability to 
convert a range of different precursors (Firn & Jones, 2003). This property is one of the 
central axioms in Screening Hypothesis, a simplified model to explain the multiplicity 
of naturally occurring secondary metabolites (Firn & Jones, 2000; Firn & Jones, 2003). 
According to the model, broad enzyme substrate specificity is favored as a way to 
efficiently increase chemical diversity at low metabolic cost (Firn & Jones, 2003) (as 
opposed to the strictly defined reactions in primary metabolism where such redundancy 
could have drastic effects and impair viability). In essence, it allows the generation of 
new functional gene combinations in nature, and specifically, explains how the genetic 
flexibility characteristic to Streptomyces biosynthetic clusters (discussed in chapter 
1.2.4) is manifested at enzyme level. To provide further product diversity, it also 
enables enzymes to convert biosynthetic intermediates of parallel co-existing 
pathways, a phenomenon frequently observed as unexpected endogenous reactions in 
vivo. In parallel, broad substrate specificity is a basis for various research applications 
that employ genetic engineering techniques to combine and reorganize genetic material 
from different biosynthetic origins.  
As postulated, it has become a generally accepted fact that enzymes involved in type II 
aromatic polyketide biosynthesis display relatively relaxed substrate specificity. 
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Provided that the atoms which directly encage in the reaction are preserved, many of 
the tailoring enzymes tolerate rather extensive variation in substrate chemical structure, 
size (Kim et al., 2007; Pacholec et al., 2005), aglycone ring frame topology (Decker & 
Haag, 1995), substitution (Dickens et al., 1997; Jansson et al., 2004) and/or 
glycosylation patterns (Jansson et al., 2003b). In the present work the property was 
demonstrated by AknH in vitro (III). It was shown to readily convert NAME, which in 
comparison to the biological substrate AAME, has a methyl instead of an ethyl 
substituent attached on the reacting carbon C9.  
The underlying determinants of relaxed substrate specificity have not been well 
described, yet recently, enzyme structure/function characterization has revealed some 
general factors concerning substrate binding, active site topology and ligand geometry. 
The enzyme binding pockets are typically composed of batches of hydrophobic 
residues, which pack against the non-polar aromatic aglycone ring system and the 
sugar residues. Active site amino acid conservation between orthologous/homologous 
enzymes is rather low, yet most mutations are conservative, and retain the hydrophobic 
nature of the pocket (Beinker et al., 2006; Jansson et al., 2003b; Jansson et al., 2004). 
In agreement with the expected relaxed substrate specificity, substrate recognition and 
binding are often primarily defined by relatively unspecific interactions (II; Alexeev et 
al., 2007; Jansson et al., 2003b; Jansson et al., 2004; Jansson et al., 2005; Sciara et al., 
2003;). The main physical forces involved are hydrophobic and van der Waals 
interactions (Bolam et al., 2007), and instead of a network of strictly defined hydrogen 
bonds, recognition appears to be determined by the overall topology, polarity and 
shape of the active site cavity. Typically only one or few of many possible hydrogen 
bonds are observed between the ligand and the active site residues (II; Jansson et al., 
2003b; Jansson et al., 2004; Jansson et al., 2005), although additional indirect 
hydrogen bonds may be formed via water molecules located in the active site.  
The research has in some cases provided direct molecular-level information on why 
some potential ligands do not function as substrates for specific enzymes. For example 
RdmC, which catalyses C15 demethoxylation of various anthracycline precursors, only 
converts compounds which are glycosylated. Although the sugar residues point away 
from the active site cavity and do not directly participate in the reaction, they have an 
important orientational role in substrate alignment through a hydrogen bond formed 
between the enzyme and the first carbohydrate moiety (Jansson et al., 2003b). In 
comparison, unlike RdmC which does not discriminate between mono- and 
triglycosylated ligands, DnrK exclusively accepts substrates with a single sugar 
substituent. Structural analysis has suggested that the alignment of larger glycosyl 
groups is prevented by enzyme conformational change induced upon binding (Jansson 
et al., 2004). Detailed understanding on such interactions could generate new 
possibilities for rational pathway design, and tools to replace approaches which simply 
rely on trial and error. This has already been demonstrated in practice, as structural 
information on substrate recognition and catalysis has been used to screen for 
functional ligands for DnrK in silico (Kim et al., 2007). 
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4.5.3 Unusual enzyme mechanisms and substrate-induced stabilization  
Characterization of enzymes involved in aromatic polyketide biosynthesis has revealed a 
number of unusual catalytic mechanisms, which differ from those described for typical 
model enzymes or homologs of known function. Based on detailed structure/ function 
analysis some of these enzymes lack cofactors usually required for catalysis. Besides 
SnoaL (II) and AknH (III), examples include oxygenase Act VA-Orf6 (Sciara et al., 
2003) and aclacinomycin 10-hydroxylase RdmB (Jansson et al., 2005). In several other 
cases, specific catalytic residues (indispensable for catalysis) have not been detected in 
combined structure comparison and targeted mutagenesis analysis. This has been 
demonstrated by PgaE (IV) tetracenomycin F2 cyclase (Thompson et al., 2004) and O-
methyltransferase DnrK in daunorubicin biosynthesis (Jansson et al., 2004) in which 
specific activities were only moderately affected upon substitution of putative catalytic 
bases essential for substrate deprotonation in related proteins. In addition, there are 
examples of enzymes which differ mechanistically from their homologs in some other 
aspects. These include PgaM described in this study (V-VI) and RdmB, which closely 
resembles typical methyltransferases in structure (Jansson et al., 2003a), but exclusively 
catalyses hydroxylation (Jansson et al., 2005). These unusual enzymes do not share a 
common fold or function, and intriguingly, the only obvious unifying theme is that they 
all catalyse reactions of related highly conjugated polycyclic substrates. 
It appears that the observed mechanistic properties are at least in part linked with the 
chemical nature of the substrate ring scaffold. It has been postulated that the substrate 
may adopt a direct catalytic role in reaction initiation and/or transition state stabilization 
(II; Fetzner, 2007; Jansson et al., 2005; Sciara et al., 2003), in analogy to the function of 
transition metal ions, flavin or pterin cofactors used by many enzymes. As per the 
organic cofactors, aromatic polyketides are characterized by polycyclic structures with 
multiple conjugated double bonds. For example AKV contains eight conjugated double 
bonds distributed over a four-ringed antracene quinone frame. Such structures allow 
efficient delocalization of the aglycone π electrons over an extended aromatic or 
aromatic-like system, which promotes charge distribution and stability of deprotonated 
reaction intermediates. This in turn reduces the free energy of transition state which must 
be overcome to drive the reaction forward. The phenomenon was first observed with the 
cofactorless oxygenase Act VA-Orf6 from S. coelicolor, which employs the substrate 
ring system to overcome the energy barrier of oxygen activation (Sciara et al., 2003). An 
equivalent mode of action has been reported for aclacinomycin 10-hydroxylase (RdmB) 
(Jansson et al., 2005), which uses delocalization of the π electrons over the substrate 
aromatic ring system for carbanion intermediate stabilization and oxygen activation. This 
model of substrate-induced stabilization has been mostly discussed in context with 
enzymes involved with oxygen chemistry (Fetzner, 2007) but as exemplified by SnoaL 
(II), the principle is not confined to this group of enzymes alone.  
Additional reactivity is provided by the presence of multiple hydroxyl and keto groups, 
typical substituents of polyketide pathway intermediates. They contribute to charge 
distribution in the ring system by enabling keto-enol tautomerization, and in parallel, 
may facilitate substrate deprotonation. Specifically, α-hydrogen atoms adjacent to 
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carbonyl oxygen groups are expected to be removed with relative ease in the 
hydrophobic environment of the active site pocket. This deprotonation would produce 
a reactive carbanion species able to readily undergo further reactions. Such “substrate-
facilitated proton abstraction" may, in part, explain the redundancy of typical catalytic 
residues observed in some enzymes, and has been suggested as the initial reaction step 
in the cyclization reaction catalyzed by SnoaL (II) and hydroxylation reaction 
catalysed by PgaM (VI).  
4.5.4 Multifunctional enzymes 
Another intriguing property associated with some of the enzymes is multifunctionality; 
participation of a single gene product in several sequential reactions. Such enzymes have 
been found in various type II polyketide biosynthetic pathways (VI; Alexeev et al., 2007; 
Chen et al., 2005; Dickens et al., 1997; Mayer et al., 2005; Rafanan et al., 2000), and 
take part in different oxygenation, reduction and/or dehydration reactions. The 
experimental findings presented in this study showed that the reaction sequence 
catalyzed by PgaE and PgaM involve five distinct reactions, two hydroxylation steps, 
hydroxyquinone oxidation, ketoreduction and dehydration (VI). The possible 
mechanisms of this multistep reaction have been covered in chapters 4.3.4 and 4.3.7. 
Other examples include homologous enzymes TcmG and ElmG, which both catalyse 
three stepwise hydroxylations in tetracenomycin biosynthesis (Rafanan et al., 2000). The 
reactions follow an intricate monoxygenase-dioxygenase mechanism, involving oxirane 
ring opening by a molecule of H2O to introduce two oxygen atoms from O2 and a single 
water-derived oxygen. Also cytochrome P-450 enzyme DoxA in doxorubicin 
biosynthesis is responsible for three oxygenation events. It catalyses hydroxylation and 
subsequent keto group formation at C13, together with the spontaneous dehydration of a 
dihydroxy intermediate, and hydroxylation of C14 (Dickens et al., 1997; Walczak et al., 
1999). The phenomenon is not restricted to the aromatic substrate systems alone, but is 
also observed for example in FAD-dependent oxygenase EncM (S. maritimus) which 
catalyses in vivo multiple reactions on non-aromatic, yet extremely reactive substrate in 
enterocin biosynthesis (Xiang et al., 2004). 
Although in some multifunctional enzymes the specific residues responsible for 
different reactions have been identified (Alexeev et al., 2007), the number of putative 
catalytic sites does not always correlate with the number of observed changes. This 
suggests that the reactions may involve mechanistically interlinked “spontaneous” non-
enzymatic chemical steps induced by the inherent instability of the intermediate 
products. Such unspecific (and in this case unwanted) reactivity is characteristic for the 
PKS steps, but also observed in association with the post-PKS tailoring reactions as, 
for example, dehydration (II-III), more extensive degradation (VI), or other changes 
(Jansson et al., 2003b) in vitro. It could be argued that the instability is one of the key 
factors which has contributed to the evolvement of multifunctional enzymes in 
aromatic polyketide biosynthesis; in combination with relaxed substrate specificity, 
spontaneous reactions would be expected to be an efficient way to increase natural 
secondary metabolite diversity. 
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5. CONCLUDING REMARKS 
The experimental work presented in this thesis provides detailed information on the 
enzymology of specific reaction steps, mechanisms and interactions in selected type II 
polyketide biosynthesis routes. The results emphasize the importance of individual 
enzyme case-studies in the field of antibiotic research, because they are required to 
build up a complete, molecular-level blueprint of the reaction pathways. The high-
resolution structure/function analysis in the first part of the study (AknH and SnoaL) 
allowed us to identify some of the amino acid determinants of cyclase stereoselectivity 
in anthracycline biosynthesis. The findings implicated that the reaction product 
stereochemistry, a central chemical feature which largely determines the biological 
activity of the pathway products, may in some cases be specified by only a small 
number of residues. Such information could potentially be used for targeted enzyme-
level modification to steer a biosynthetic reaction towards a more desired 
stereochemical outcome. The enzyme in vitro characterization in the second part of the 
study (PgaE and PgaM) provided insight on the complex post-PKS oxygenation 
cascade common to many angucycline pathways. The work underlined the concepts of 
timing and coupling in successive reactions, and demonstrated that the biosynthetic 
steps are not always separable from one another, and may involve complex chemistry 
difficult to resolve in vivo. 
The results presented here are not merely isolated examples of specific phenomena, but 
may provide direct evidence of how these biosynthetic pathways have evolved. While 
the morphological, biochemical and genetic diversity of Streptomyces have been 
widely documented, reports on enzyme-level adaptation and diversification are still 
limited. This study described several cases of enzyme mechanistic adaptation: In 
comparison to characterized model enzymes, the polyketide cyclases SnoaL and AknH 
are devoid of specific functional elements (cofactor/amino-acid) usually required for 
intermediate stabilization, whereas PgaE and CabE appear to use an alternative 
mechanism for the initial catalytic step of substrate deprotonation. PgaM employs an 
unusual flavoprotein redox cycle and oxygen chemistry to bring about hydroxylation, 
and at the same time presents an interesting case of structural evolution - translational 
fusion of two ancestral reading frames. These divergences illustrate that the enzymes in 
type II aromatic polyketides are subjected to change, perhaps as a result of the need to 
adapt to rapidly changing biosynthetic contexts in response to gene-level flexibility. 
Two central factors which may contribute to the process of adaptation are high 
intermediate reactivity and broad enzyme substrate specificity characteristic to the 
biosynthetic steps. However, more extensive enzyme-level research is needed to 
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